Ectopic CRH Production from Pancreatic Tumors May Mimic Cushing Disease Due to Pituitary Corticotroph Cell Hyperplasia: The First–Ever Cases in Young Children

Autor: F Kamran, R Cherqaoui, C Kemp, M Crocker, O Jailan, M Keil, E Lange, M Tsokos, MJ Merino, M Hughes, E Kebebew, C Stratakis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42801653d8ddc421000bd85ce76c0863
https://doi.org/10.1210/endo-meetings.2010.part1.p2.p1-82

Delayed endometrial maturation incuded by daily administration of the antiprogestin RU 486: A potential new contraceptive strategy

Autor: MJ Merino, Marcelo C. Batista, DL Loriaux, LK Nieman, C Axiotis, Tannia P. Cartledge, Ann W. Zellmer

Publikováno v: International Journal of Gynecology & Obstetrics. 40:270-271

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13fe6323e690e5ec32f1c65b89a93018
https://doi.org/10.1016/0020-7292(93)90872-t

Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer

Autor: Nj, Mccarthy, Yang X, Ir, Linnoila, Mj, Merino, Stephen Hewitt, Al, Parr, Paik S, Sm, Steinberg, Dp, Hartmann, Mourali N, Ph, Levine, Sm, Swain

Publikováno v: Europe PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::05469d2f9261f43390d6d45cf299e7ee
http://europepmc.org/abstract/med/12473600

A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis.

Autor: Gelikman DG; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Azar WS; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yilmaz EC; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lin Y; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Shumaker LA; Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA., Fang AM; Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA., Harmon SA; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Huang EP; Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Parikh SH; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hyman JA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Schuppe K; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Nix JW; Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA., Galgano SJ; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.; Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA., Merino MJ; Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Choyke PL; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gurram S; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wood BJ; Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, MD, USA., Rais-Bahrami S; Department of Urology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.; Department of Radiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA., Pinto PA; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Turkbey B; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Publikováno v: BJU international [BJU Int] 2024 Dec 09. Date of Electronic Publication: 2024 Dec 09.

External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans.

Autor: Yilmaz EC; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Harmon SA; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Law YM; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Huang EP; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Belue MJ; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Lin Y; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Gelikman DG; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Ozyoruk KB; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Yang D; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Xu Z; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Tetreault J; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Xu D; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Hazen LA; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Garcia C; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Lay NS; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Eclarinal P; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Toubaji A; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Merino MJ; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Wood BJ; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Gurram S; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Choyke PL; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Pinto PA; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.)., Turkbey B; From the Molecular Imaging Branch (E.C.Y., S.A.H., M.J.B., Y.L., D.G.G., K.B.O., N.S.L., P.E., P.L.C., B.T.), Biometric Research Program, Division of Cancer Treatment and Diagnosis (E.P.H.), Center for Interventional Oncology (L.A.H., C.G., B.J.W.), Department of Radiology, Clinical Center (L.A.H., C.G., B.J.W.), Laboratory of Pathology (A.T., M.J.M.), and Urologic Oncology Branch (S.G., P.A.P.), National Cancer Institute, National Institutes of Health, 10 Center Dr, MSC 1182, Bldg 10, Rm B3B85, Bethesda, MD 20892; Department of Radiology, Singapore General Hospital, Singapore (Y.M.L.); and NVIDIA Corporation, Santa Clara, Calif (D.Y., Z.X., J.T., D.X.).

Publikováno v: Radiology. Imaging cancer [Radiol Imaging Cancer] 2024 Nov; Vol. 6 (6), pp. e240050.